T. Rowe Price Associates’s Aevi Genomic Medicine Inc GNMX Stock Holding History

T. Rowe Price Associates’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-276,250	Closed	-$307K	–	2621
2018 Q2	$307K	Sell	276,250 -867,560	-76%	-$1.32M	﹤0.01%	2339
2018 Q1	$2.3M	Buy	+1,143,810	New	+$2.15M	﹤0.01%	1542
2017 Q1	–	Sell	-760,167	Closed	-$3.94M	–	2609
2016 Q4	$3.94M	Sell	760,167 -3,700	-0.5%	-$19.5K	﹤0.01%	1448
2016 Q3	$4.25M	Buy	763,867 +2,667	+0.4%	+$15.2K	﹤0.01%	1443
2016 Q2	$4.22M	Sell	761,200 -3,800	-0.5%	-$20K	﹤0.01%	1420
2016 Q1	$3.37M	Hold	765,000	–	–	﹤0.01%	1445
2015 Q4	$4.61M	Buy	+765,000	New	+$5.19M	﹤0.01%	1428

Other funds holding GNMX

AMCA

Arthur M. Cohen & Associates Northbrook, Illinois $640M AUM 26.68% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

T. Rowe Price Associates's GNMX Position: Q3 2018 in Review

T. Rowe Price Associates sold out of Aevi Genomic Medicine Inc (GNMX) in Q3 2018, closing a stake of 276,250 shares — an estimated $307K sold.

T. Rowe Price Associates first reported a position in GNMX in Q4 2015 and held it in 7 quarters. The position peaked at $4.61M in Q4 2015. 44 funds tracked by Wall St. Rank hold GNMX as of Q3 2018.

T. Rowe Price Associates reported no remaining Aevi Genomic Medicine Inc position as of Q3 2018 after selling out during the quarter.
T. Rowe Price Associates sold 276,250 Aevi Genomic Medicine Inc shares in Q3 2018, an estimated $307K.
T. Rowe Price Associates first reported a position in Aevi Genomic Medicine Inc in Q4 2015 and held it in 7 quarters.
T. Rowe Price Associates's Aevi Genomic Medicine Inc position peaked at $4.61M in Q4 2015.
44 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q3 2018.

Based on T. Rowe Price Associates's 13F filing for Q3 2018, filed 14 Nov 2018.